Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 33, Issue 6, 2012, Pages 450-458

  Carr, Warner W ^a   Ratner, Paul ^b   Munzel, Ullrich ^c   Murray, Ruth ^d   Price, David ^e   Canonica, G Walter ^f   Mullol, Joaquim ^g   Virchow, J Christian ^h   Lieberman, Phil ⁱ   Meltzer, Eli ^j   Bachert, Claus ^k  

^a Allergy & Asthma Associates of Southern California   (United States)

^b Sylvana Research   (United States)

^c MEDA Pharma GmbH and Co KG   (Germany)

^d MedScript   (Ireland)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f UNIVERSITY OF GENOA   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

ⁱ UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^j ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^k GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; FLUTICASONE PROPIONATE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE DISEASE; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 84871692646     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3626     Document Type: Article

References (24)

1. Bernstein JA. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy Asthma Proc 31:356-359, 2010.
2. Meltzer EO, Blaiss MS, Naclerio RN, et al. Burden of allergic rhinitis: Allergies in America, Latin America and Asia-Pacific adult surveys. Allergy Asthma Proc 33(suppl):113-141, 2012.
3. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol 126:466-476, 2010.
4. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl):S1-S84, 2008. (Pubitemid 352033573)
5. Berger WE, and White MV; Rhinitis Study Group. Efficacy of AZE nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003. (Pubitemid 36999483)
6. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of AZE nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenddine. Ann Allergy Asthma Immunol 93:154-159, 2004. (Pubitemid 39128495)
7. Hampel FC, Rather PH, Van Bavel J, et al. Double-blind, placebo-controlled study of AZE and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 105:168-173, 2010.
8. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of AZE with fluticasone for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 129:1282-1289, 2012.
9. Meltzer EO, Laforce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 33:324-332, 2012.
10. Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol 74:125-133, 2012.
11. Food and Drug Administration NOT (FDA) Guideline. Guidance for industry. Allergic rhinitis: Clinical development programs for drug programs. U.S. Department of Health and Human Services, FDA Center for Drug Evaluation and Research, April 2000. Available online at www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071293.pdf; accessed July 23, 2012.
12. EMA guideline. Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis. CHMP/EWP/2455/02, October 2004. Available online at www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003554.pdf; accessed July 23, 2012.
13. International Committee on Harmonization Harmonized Tripartite Guidelines on Good Clinical Practice (1996). Available online at www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline. pdf; accessed July 23, 2012.
14. Juniper EF, and Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21:77-83, 1991.
15. Pitman R, Paracha N, Parker C, et al. Episode pattern and healthcare utilization in patients with seasonal allergic rhinitis. Presented at the European Allergy and Clinical Immunology (EAACI) 31st Annual Meeting, Geneva, Switzerland, June 16-20, 2012. Abstract 885.
16. Keith PK, and Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin 25:2021-2041, 2009.
17. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with AZE hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100:74-81, 2008.
18. Carr W, Ratner P, Bachert C, et al. Intranasal AZE (2 sprays/nostril bd) versus intranasal fluticasone propionate (2 sprays/nostril once daily) for the treatment of patients with seasonal allergic rhinitis over a 14-day period. Presented at European Academy of Allergology and Clinical Immunology (EAACI), Geneva, Switzerland, June 16-20, 2012. Abstract 863.
19. Lange B, Lukat KF, and Rettig K. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95:272-282, 2005. (Pubitemid 41376798)
20. Bernstein JA. AZE hydrochloride: A review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 23:2441-2452, 2007. (Pubitemid 350033446)
21. Lee C, and Corren J. Review of AZE nasal spray in the treatment of allergic and non-allergic rhinitis. Expert Opin Pharmacother 8:701-709, 2007. (Pubitemid 46547022)
22. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expressed on nasal epithelial cells: An antiallergic activity. J Allergy Clin Immunol 98:1088-1096, 1996. (Pubitemid 27014802)
23. Wang D, Smitz J, De Waele M, et al. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 114:185-192, 1997. (Pubitemid 27397074)
24. Lieberman PL, and Settipane RA. Azelastine nasal spray: A review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc 24:95-105, 2003. (Pubitemid 37034194)